Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

U S Physical Therapy (USPH) Receivables (2016 - 2025)

U S Physical Therapy's Receivables history spans 12 years, with the latest figure at $22.4 million for Q3 2023.

  • For Q3 2023, Receivables rose 1.93% year-over-year to $22.4 million; the TTM value through Sep 2023 reached $22.4 million, up 1.93%, while the annual FY2022 figure was $55.5 million, 19.94% up from the prior year.
  • Receivables for Q3 2023 was $22.4 million at U S Physical Therapy, up from $20.6 million in the prior quarter.
  • Across five years, Receivables topped out at $55.5 million in Q4 2022 and bottomed at $9.9 million in Q3 2020.
  • The 5-year median for Receivables is $22.5 million (2022), against an average of $31.0 million.
  • The largest annual shift saw Receivables soared 644.82% in 2019 before it tumbled 79.04% in 2020.
  • A 5-year view of Receivables shows it stood at $46.2 million in 2019, then decreased by 9.35% to $41.9 million in 2020, then increased by 10.42% to $46.3 million in 2021, then increased by 19.94% to $55.5 million in 2022, then tumbled by 59.7% to $22.4 million in 2023.
  • Per Business Quant, the three most recent readings for USPH's Receivables are $22.4 million (Q3 2023), $20.6 million (Q2 2023), and $21.5 million (Q1 2023).